Neogene Therapeutics IPO

Neogene Therapeutics develops personalized engineered T cell therapies for a broad spectrum of cancers.

Register for Details

For more details on financing and valuation for Neogene Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Neogene Therapeutics Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
9/14/2020 Series A $110MM raised $XXX.XX $XXX.XX
5/23/2019 Series Seed $15MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about Neogene Therapeutics

Forge green plus iconForge green minus icon

What is Neogene Therapeutics funding to date?

Neogene Therapeutics has raised $125MM with the following series:
$15MM raised for Series Seed,$110MM raised for Series A.
Forge green plus iconForge green minus icon

When was Neogene Therapeutics founded?

Neogene Therapeutics was founded in 2018.
Updated on: Jun 12, 2022